About BioMark

Providing universal access to cancer diagnostics and early stage detection by leveraging the power of new technology.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

Who We Are

Oncology Focused, Predictive Accuracy

BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the detection and quantitation of metabolites.
Our global enterprise team of proven scientists, engineers and medical professionals is hand-picked. The company’s goal is to commercialize our innovative technology. And we strive to increase the predictive accuracy in early stage cancer detection. We adhere to and follow the highest regulatory, clinical and scientific standards.
Since 2007, our mission and team commitment remains the same. Develop and commercialize innovative technologies. Increase the prediction and accuracy of early stage diagnosis of cancers.
biomark diagnostics oncology detection cancer ribbon
biotechnology, medical biotechnology, cancer research
empowering oncologists and physicians with early stage cancer detection tools
oncology, biotech company, breast cancer research

We Why Are

Empowering People

It’s not only about physicians and medical institutions. Our goal is to empower people and nations. To provide universal access to effective cancer diagnostic tools.
At BioMark we speed up and make available effective cancer management solutions. We strive to improve patient outcomes.

Adherence To Rigorous Standards

Biomarkers play a critical role in all stages of disease. This is why rigorous evaluation is important. Analytical validation, clinical validation, and assessment of clinical utility. Each is important before the incorporation of routine clinical care. This is an important dimension of BioMark’s daily operational activity.

biotechnology, medical biotechnology, cancer research

Rashid Ahmed Bux: BioMark Diagnostics Response to Treatment

BioMark Diagnosis Cancer Survivorship Program

Rashid Ahmed Bux: BioMark Diagnostics Screening Tool

BioMark's Team

The collective core leadership team consists of research scientists and doctors. Each with decades of diagnostic development, engineering, and biochemistry experience. Additionally, BioMark’s team consists of well experienced business professionals and leaders. The team’s goal is to drive discovery, and reduce regulatory and technical risks. We are passionate to speed up clinical adoption and work with biopharma.

Executive Team

Rashid Ahmed Bux, MBA – Founder, Chief Executive Officer

Dr. Jeff Haince, Ph.D – Chief Scientific Officer and GM

Dr. Bram Ramjiawan, Ph.D – Clinical Trial and Regulatory Expertise

Brian Cheng, MSc– Chief Technical Officer

Gina Huang, MBA – CFO and Project Director

Research, Scientific, Clinical

Dr. Daniel Sitar – Principal Scientific Advisor / Professor Emeritus, University of Manitoba

Dr. David Wishart – Professor, Depts. of Computer Science and Biological Sciences, University of Alberta

Dr. Myron L. Weisfeldt – M.D., University Distinguished Service Professor, Professor of Medicine, The Johns Hopkins Hospital

Dr. Andrew Maksymiuk – Oncologist; Cancer Care Manitoba

Dr. Reuven Gordon – Professor, Canadian Research Chair in Nanoplasmonics, University of Victoria

Dr. Paramjit Tappia – Scientific and Clinical Researcher, St. Boniface Research Centre

Dr. John Yoo – Clinical Oncologist; Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario

Dr. Donald Miller – Professor, Department of Pharmacology and Therapeutics University of Manitoba

Dr. David Chen – Professor, Dept. of Chemistry, University of British Columbia

Dr. Horacio Bach – PhD, Antibody Engineering UBC

Alfred Berkeley – Strategic and financial advisor


USA Clinical Research

Dr. Greame F. Woodworth (MD) will be leading the initial Glioblastoma Multiforme resection. The goal is to correlate Glioblastoma Multiforme resection to existing anatomical imaging tests. Dr. Woodworth is a Professor at the University of Maryland, Department of Neurosurgery. He is also the Director of the Brain Tumor Treatement and Research Center. DR. Woodworth will serve as the University’s principle investigator for the study.
The co-PI is Dr. Chetan Bettegowda of Johns Hopkins. He serves as the Director Meningioma Center and Associate Professor of Neurosurgery.
Dr. Christian D. Rolfo (MD, PhD, MBA) will lead BioMark’s lung cancer panel. The panel validates the study and use in early lung cancer screening initiatives. The panel also handles measuring the response to treatments. Dr. Rolfo is a Professor, Department of Medicine. He is also the Director, Early Phase Clinical Trials Department of Medicine. And he is the Director, Thoracic Medical Oncology – Department of Medicine. Dr. Rolfo will serve as UMB’s principal investigator in connection with such study(ies).
early stage cancer detection - gliobastoma multiforme resection and anatomical imaging tests
biotechnology, medical biotechnology, cancer research

Kudos and Accolades

Executive Team & Advisors

Cross Pollinated, Balanced and Committed team since 2007.

Cancer Diagnostics

BioMark Pushing the Limit of Early Detection.

Awards, Grants, Recognitions

Sparks Grant, TMIC University of Alberta - Dr. David Wishart

Strategic Collaborations

Biopharmaceutical Research Inc. & University of Manitoba



Legal Counsel

Legal Counsel: Cozen O’Connor, British Columbia

Legal Counsel: Norton Rose Fulbright Canada, Quebec

Legal Counsel – Patent: ROBIC LLP, Quebec

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.